User News: The Endometriosis Health Profile (EHP) used to gather evidence in clinical trial of improved Quality of Life (QoL) in women with Endometriosis-associated pain

8th November 2021

The Endometriosis Health Profile (EHP)-30 successfully employed as part of a Randomized Control Trial to assess whether O-118 - Reglugolix combination therapy improves multiple dimensions of quality of life in women with Endometriosis-associated pain.

“Endometriosis has a significant impact on women’s physical, social, and emotional life. In the SPIRIT trials, relugolix combination therapy (Rel-CT: relugolix 40 mg, estradiol 1 mg, norethindrone acetate 0.5 mg) significantly reduced dysmenorrhea, non-menstrual pelvic pain (NMPP) and dyspareunia vs placebo in premenopausal women with endometriosis-associated pain. Here, the effect of Rel-CT on health-related quality of life (QoL) domains, assessed using the Endometriosis Health Profile (EHP)-30 questionnaire, are reported”, showing at Week 24, the EHP-30 total score and all domain scores were improved significantly with Rel-CT.

The EHP is particularly appropriate for use in clinical trials to assess the effectiveness of medical or surgical therapies for endometriosis on the HRQoL of affected women. For this reason the EHP has been used by four of the top twenty global pharmaceutical companies, supporting numerous clinical trials.

Read the full article here: https://asrm.confex.com/asrm/2021/meetingapp.cgi/Paper/10852

Press release sign up